TG Therapeutics (TGTX) Issues Regulatory Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
November 30, 2021 12:55 PM ESTGoldman Sachs analyst Corinne Jenkins lowered the price target on TG Therapeutics (NASDAQ: TGTX) to $13.00 (from $26.00) while maintaining a Sell rating as the ODAC raises new questions on benefit/risk of U2 in CLL.
"Timing of approval decision likely delayed, approvability of U2 in CLL in question," the analyst notes.
... More
